🏛️ Verified NIH Record • Updated 2026-05-28
Study With Various Immunotherapy Treatments in Participants With Lung Cancer (NCT05676931)
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Gilead Sciences
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tolerability of immunotherapy-based combination therapy.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (6 items).
Location: University of Alabama at Birmingham (UAB) — Birmingham, Alabama
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Underlying medical conditions that, in the Investigator's or Sponsor's opinion, will make the administration of Investigational Product(s) (IPs) hazardous
- Use of any live vaccines against infectious diseases within 28 days of first dose of IP(s).
- Use of supra-physiologic doses of corticosteroids (\> 10 mg/day of oral prednisone or equivalent) or immunosuppressive medications ≤ 14 days before the initiation of study treatment (absorbable topical corticosteroids are not excluded).
- Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- Any active autoimmune disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for vitiligo or resolved childhood asthma/atopy NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (53 Sites)
- University of Alabama at Birmingham (UAB) — Birmingham, Alabama
- University of California San Diego (UCSD) — La Jolla, California
- Memorial Cancer Institute at Memorial Regional Hospital — Hollywood, Florida
- Hematology Oncology Associates Of The Treasure Coast — Port Saint Lucie, Florida
- Florida Cancer Specialists (Administration and Drug Shipment) — The Villages, Florida
- Northwestern Memorial Hospital — Chicago, Illinois
- Ochsner Clinic Foundation — Jefferson, Louisiana
- Henry Ford Hospital — Detroit, Michigan
- Virginia Cancer Specialists, PC — Fairfax, Virginia
- Medical Oncology Associated, PS (dba Summit Cancer Centers) — Spokane, Washington
- The Border Cancer Hospital — Albury, New South Wales
- Pindara Private Hospital — Benowa, Queensland
- Cancer Research SA Pty Ltd — Adelaide, South Australia
- Sir Charles Gairdner Hospital — Nedlands, Western Australia
- CHU Bordeaux Centre Francois Magendie Hôpital du Haut Lévèque — Bordeaux,
- Hospices Civils de Lyon Centre Hospitalier Lyon Sud — Lyon,
- Institut De Cancerologie Strasbourg Europe ICANS — Strasboug,
- Hopital FOCH — Suresnes,
- LTD High Technology Hospital Medcenter — Batumi,
- Caucasus Medical Center — Tbilisi,
- Israel Georgian Medical Research Clinic Healthycore — Tbilisi,
- JSC K. Eristavi National Center of Experimental and Clinical Surgery — Tbilisi,
- Ltd Pineo Medical Ecosystem — Tbilisi,
- Istituto Romagnolo per lo Studio dei Tumori-Dino Amadori - IRST — Meldola,
- stituto Nazionale per lo Studio e la Cura dei Tumori — Milan,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.